CA2742389A1 - Topical treatment of skin infection - Google Patents
Topical treatment of skin infection Download PDFInfo
- Publication number
- CA2742389A1 CA2742389A1 CA2742389A CA2742389A CA2742389A1 CA 2742389 A1 CA2742389 A1 CA 2742389A1 CA 2742389 A CA2742389 A CA 2742389A CA 2742389 A CA2742389 A CA 2742389A CA 2742389 A1 CA2742389 A1 CA 2742389A1
- Authority
- CA
- Canada
- Prior art keywords
- acne
- propylene glycol
- salicylic acid
- rosacea
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
Abstract
The invention relates to an unexpected discovery that propylene glycol is highly effective at killing or inhibiting Propionibacterium acnes in a mammalian skin disorder, as well as to the use of propylene glycol and salicylic acid in a skin- disorder treatment. This invention also relates to compositions containing propylene glycol alone or in combination with salicylic acid for use in killing or inhibiting Propionibacterium acnes.
Description
TOPICAL TREATMENT OF SKIN INFECTION
This application is being filed on 28 September 2009, as a PCT International Patent application in the name of Win L. Chiou, a citizens of the U.S., applicant for the designation of all countries, and claims priority to U.S. Utility patent application Serial No. 12/244,924, filed October 3, 2008.
Field of the Invention The invention relates to an unexpected discovery that propylene glycol is highly effective at killing or inhibiting Propionibacterium acnes in a mammalian skin disorder, as well as to the use of propylene glycol and salicylic acid in a skin-disorder treatment. This invention also relates to compositions containing propylene glycol alone or in combination with salicylic acid for use in killing or inhibiting Propionibacterium acnes.
Background of the Invention Acne is a common skin disorder. Many topical and systemic treatment methods are available ("Handbook of Nonprescription Drugs,"-American Pharmaceutical Association, 2002, pages 777 - 791; Katsambas and Dessiniot, Dermatologic Therapy, 21:86-95, 2008). A major shortcoming of the current treatment methods is their slow response often requiring several months of daily application or administration. Furthermore, satisfactory results achieved are often only about 40% to 60% (Chiou, 2007, US patent no. 7,258,875 B2). Multiple (3 to 4) treatment steps are often required. Skin dryness and irritation are common;
pitting or scarring may occur after treatment. Serious adverse effects can also occur for potent drugs. Although natural polyvalent metal compounds are recently employed to treat acne (Chiou, 2007, US patent no. 7,258,875 B2), the stickiness of products due to the glycerin and thickening agent employed is a major drawback not acceptable by many patients in spite of their efficacy (unpublished observation).
This is also the case in treating rosacea (Chiou, 2007, US patent no.
7,258,875 B2).
The above review indicates a need to develop a new, cosmetically-acceptable, simple, one-step, highly safe and highly effective method for topically treating acne and rosacea without scarring and pitting. Ideally, the new drug treatment may not require a prescription and the same preparation can be used to treat both disorders. The present invention is aimed to achieve the above objectives.
This is made possible by a surprising discovery that a commonly used, highly safe and rapidly absorbed (unpublished observation) compound possesses a strong in vitro bactericidal activity against Propionibacterium acnes, that is mainly responsible for the infection in acne. Many other factors are known to contribute to the occurrence of acne and vastly different approaches have been used to tackle the acne disorder. Interestingly, the same compound can also be used to treat infection in rosacea.
Summary of the Invention Propylene glycol (PG) is a colorless, odorless, sweet, light liquid. It has been widely employed for almost a century in skin-care products as a solvent, humectant, skin-conditioning agent and viscosity-decreasing agent ("International Cosmetic Ingredients Dictionary and Handbook", 2004, page 1536). It is listed as an inactive ingredient in dermatological drugs approved for marketing to date.
The concentrations used generally are low ranging from about one to several percent.
The present invention discloses a very surprising, novel discovery that high concentrations of PG in vitro can very effectively kill P. acnes (Example 1), and without the need for any special prior cleansing or treatment, high (such as 20% to 80% by weight) aqueous PG solutions can virtually heal various sizes of infectious (pustular or papular) acne in about 0.5 to 2-3 days after one to several topical applications without pitting and scarring (Examples 2-4). No adverse effects were observed for solutions containing up to 75% or 80% PG (Examples 3-7). Pure (100%) PG and 90% PG solutions (Example 5) caused no noticeable adverse effects on normal skin (Example 5). Daily use of the 75% or 80% PG solution showed excellent prophylactic effect against new acne formation (Example 4). An aqueous solution containing 75% PG and 0.5% salicylic acid was highly effective against acne and rosacea without adverse reactions (Example 6).
Therefore, the present invention provides a highly effective, highly safe, novel method for killing and inhibiting P. acnes in mammalian skin disorder consisting essentially of, or comprising topically applying a therapeutically effective amount of PG alone or in combination with a therapeutically effective amount of salicylic acid or other anti-acne compounds in a pharmaceutically acceptable dosage form to the area of skin disorder; one such skin disorder is acne. The above approach is also highly effective in treating rosacea.
Therefore, the present invention provides a very novel, simple, one-step and extremely effective and safe method for treating acne and rosacea consisting essentially of, or comprising topically applying a therapeutically effective amount of PG alone or in combination with a therapeutically effective amount of salicylic acid or other anti-acne or anti-rosacea compounds in a dosage form to the area of skin lesion. The rationale and advantages of the novel combination of PG and salicylic acid will be discussed below.
Detailed Description of the Invention As used herein, the word "treatment" or "treating" includes killing and/or inhibiting P. acnes in skin, ameliorating or resolving the symptoms of, or healing, and preventing the development of acne or rosacea in mammals. It also may include helping or potentially helping ameliorate or resolve the symptoms of, cure or heal and prevent the development of acne or rosacea breakouts. It also may include the anti-acne or anti-rosacea effect or management. The phrase "effective amount"
refers to that amount of PG or salicylic acid, which is sufficient for effective treatment when administered topically to any mammal in need of such treatment.
The word "prevention" refers to prophylaxis. The phrase "dosage form" refers to, but is not limited to, the following: a liquid solution or mixture, suspension, gel, lotion, emulsion, paste, cream, spray or a medicated bandage, pad or mask. The method to prepare a dosage form is based on standard principles and methods described in various pharmaceutical literature. The phrase "salicylic acid"
refers to salicylic acid or salicylate.
Concentrations of PG and other ingredients described in this application are all based on weight. The effective concentration of PG may range from about 5%
to about 100%, about 8% to about 100%, about 10% to about 100%, about 15% to about 100%, about 20% to about 100%, about 25% to about 100%, about 50% to about 100%, about 10% to about 90%, about 15% to about 90%, and about 20% to about 90%, or preferably from about 25% to about 85% or from about 50% to about 90%. Use of pure (100%) PG is expected to produce the most dramatic effect of killing P. acnes. However, it may cause some minor skin irritation to the lesion of acne or to sensitive skin. Inclusion of some glycerin such as 5% to 20%
soothes the skin and eliminates the itching and tingling caused by PG (Example 2).
The dosage form used may include a suitable amount of water, glycerin, other solvent(s), electrolyte(s), pH modifier(s), surfactant(s), absorption enhancer(s), emulsifier(s), thickener(s), fragrant(s), preservative(s), or a mixture thereof.
Although not required, the dosage form may also include one or more optional or additional anti-acne ingredients, including but not limited to salicylic acid, salicylate, benzoyl peroxide, metronidazole, erythromycin, tetracyclines and their derivatives, macrolides, clindamycin, minocycline, mecloycline, cloxycycline, azithromycin, clarithromycin, retinoids, azelaic acid, polyvalent metal compounds, picolinic acids, dapsone, anti-inflammatory compounds and astringents or a mixture thereof.
Salicylic acid is a Food-and-Drug-Administration-approved over-the-counter drug for treating acne because of its comedolytic property. This, and benzoyl peroxide, an anti-P. acnes drug, and many other ingredients (up to 30 or more) are often employed to form a 3- or 4- step treatment regime for acne. Skin dryness and irritation is a known problem associated with the above regime.
The novel combination of the PG and salicylic acid in a liquid solution in the present invention offers many unique and important advantages such as high efficacy for both infectious (pustular or papular) and non-infectious (whiteheads and blackheads in Example 6) components of acne, very low potential for allergic and adverse effects (both compounds being natural compounds), soothing, moisturizing, smoothing and firming effect on skin (Example 7), causing no pitting and scarring, a simple one-step method or a simple "all-in-one" method, great convenience for travelers (not carrying 3 or 4 bottles) and apparent economy. Furthermore, it can be used for rosacea treatment (Example 7). The present invention may also be useful to treat other bacterial skin infections. The concentration of salicylic acid or salicylate may range from about 0.05% to about 2% or from about 0.05% to about 3% or about 0.05% to about 6%. The dosage form may include glycerin ranging from about 5%
to about 20% for skin-soothing effect (Example 2).
For killing or inhibiting P. acnes or for treating acne or rosacea breakouts, dosage preparation can be applied as thin layers up to several times a day to the area of lesions or prophylactically to the area that may have new breakouts later.
Therefore, the present invention provides a novel method for treating acne and rosacea consisting essentially of, or comprising-topically applying a therapeutically effective amount of propylene glycol in the absence or presence of a therapeutically effective amount of salicylic acid or other anti-acne or anti-rosacea compounds in a pharmaceutically acceptable dosage form to the area of lesion of acne or rosacea.
The present invention is illustrated by the following non-limiting examples.
Examples Example 1 20% and 65% PG in Water for in vitro Time-Kill Studies An aqueous solution containing 20 or 65% PG was prepared by mixing PG
and water in a proper proportion for the standard time-kill study using Propionibacterium acnes ATCC #6919. For the 20% PG solution 47% and 98% of the bacteria were killed at one and five hours, respectively. For the 65% PG
solution 91 % and 99.6% of the bacteria were killed at one in and five hours, respectfully.
The initial bacteria count was 1.78 x 106 CFU/mL. Much higher PG solutions are expected to produce much higher killing rates.
Example 2 80% PG in Water for Acne Treatment: A Dramatic Effect The above aqueous PG solution was directly applied as thin layers to several infectious papular acnes in the forehead of an adult. The infection (inflammation) appeared to completely disappear in 8 hours indicating a virtual healing only after one application. On another day, a larger papular acne was also practically healed in about 8 hours after only one application without scarring and pitting. Mild itching and tingling lasting about three minutes occurred in both studies. These minor adverse effects were totally avoided when some glycerin (about 10%) was added to the mixture. No special cleansing of the lesion or skin is required for all the studies described here and below, hence it is a truly simple one-step method or "all-in-one"
method.
This application is being filed on 28 September 2009, as a PCT International Patent application in the name of Win L. Chiou, a citizens of the U.S., applicant for the designation of all countries, and claims priority to U.S. Utility patent application Serial No. 12/244,924, filed October 3, 2008.
Field of the Invention The invention relates to an unexpected discovery that propylene glycol is highly effective at killing or inhibiting Propionibacterium acnes in a mammalian skin disorder, as well as to the use of propylene glycol and salicylic acid in a skin-disorder treatment. This invention also relates to compositions containing propylene glycol alone or in combination with salicylic acid for use in killing or inhibiting Propionibacterium acnes.
Background of the Invention Acne is a common skin disorder. Many topical and systemic treatment methods are available ("Handbook of Nonprescription Drugs,"-American Pharmaceutical Association, 2002, pages 777 - 791; Katsambas and Dessiniot, Dermatologic Therapy, 21:86-95, 2008). A major shortcoming of the current treatment methods is their slow response often requiring several months of daily application or administration. Furthermore, satisfactory results achieved are often only about 40% to 60% (Chiou, 2007, US patent no. 7,258,875 B2). Multiple (3 to 4) treatment steps are often required. Skin dryness and irritation are common;
pitting or scarring may occur after treatment. Serious adverse effects can also occur for potent drugs. Although natural polyvalent metal compounds are recently employed to treat acne (Chiou, 2007, US patent no. 7,258,875 B2), the stickiness of products due to the glycerin and thickening agent employed is a major drawback not acceptable by many patients in spite of their efficacy (unpublished observation).
This is also the case in treating rosacea (Chiou, 2007, US patent no.
7,258,875 B2).
The above review indicates a need to develop a new, cosmetically-acceptable, simple, one-step, highly safe and highly effective method for topically treating acne and rosacea without scarring and pitting. Ideally, the new drug treatment may not require a prescription and the same preparation can be used to treat both disorders. The present invention is aimed to achieve the above objectives.
This is made possible by a surprising discovery that a commonly used, highly safe and rapidly absorbed (unpublished observation) compound possesses a strong in vitro bactericidal activity against Propionibacterium acnes, that is mainly responsible for the infection in acne. Many other factors are known to contribute to the occurrence of acne and vastly different approaches have been used to tackle the acne disorder. Interestingly, the same compound can also be used to treat infection in rosacea.
Summary of the Invention Propylene glycol (PG) is a colorless, odorless, sweet, light liquid. It has been widely employed for almost a century in skin-care products as a solvent, humectant, skin-conditioning agent and viscosity-decreasing agent ("International Cosmetic Ingredients Dictionary and Handbook", 2004, page 1536). It is listed as an inactive ingredient in dermatological drugs approved for marketing to date.
The concentrations used generally are low ranging from about one to several percent.
The present invention discloses a very surprising, novel discovery that high concentrations of PG in vitro can very effectively kill P. acnes (Example 1), and without the need for any special prior cleansing or treatment, high (such as 20% to 80% by weight) aqueous PG solutions can virtually heal various sizes of infectious (pustular or papular) acne in about 0.5 to 2-3 days after one to several topical applications without pitting and scarring (Examples 2-4). No adverse effects were observed for solutions containing up to 75% or 80% PG (Examples 3-7). Pure (100%) PG and 90% PG solutions (Example 5) caused no noticeable adverse effects on normal skin (Example 5). Daily use of the 75% or 80% PG solution showed excellent prophylactic effect against new acne formation (Example 4). An aqueous solution containing 75% PG and 0.5% salicylic acid was highly effective against acne and rosacea without adverse reactions (Example 6).
Therefore, the present invention provides a highly effective, highly safe, novel method for killing and inhibiting P. acnes in mammalian skin disorder consisting essentially of, or comprising topically applying a therapeutically effective amount of PG alone or in combination with a therapeutically effective amount of salicylic acid or other anti-acne compounds in a pharmaceutically acceptable dosage form to the area of skin disorder; one such skin disorder is acne. The above approach is also highly effective in treating rosacea.
Therefore, the present invention provides a very novel, simple, one-step and extremely effective and safe method for treating acne and rosacea consisting essentially of, or comprising topically applying a therapeutically effective amount of PG alone or in combination with a therapeutically effective amount of salicylic acid or other anti-acne or anti-rosacea compounds in a dosage form to the area of skin lesion. The rationale and advantages of the novel combination of PG and salicylic acid will be discussed below.
Detailed Description of the Invention As used herein, the word "treatment" or "treating" includes killing and/or inhibiting P. acnes in skin, ameliorating or resolving the symptoms of, or healing, and preventing the development of acne or rosacea in mammals. It also may include helping or potentially helping ameliorate or resolve the symptoms of, cure or heal and prevent the development of acne or rosacea breakouts. It also may include the anti-acne or anti-rosacea effect or management. The phrase "effective amount"
refers to that amount of PG or salicylic acid, which is sufficient for effective treatment when administered topically to any mammal in need of such treatment.
The word "prevention" refers to prophylaxis. The phrase "dosage form" refers to, but is not limited to, the following: a liquid solution or mixture, suspension, gel, lotion, emulsion, paste, cream, spray or a medicated bandage, pad or mask. The method to prepare a dosage form is based on standard principles and methods described in various pharmaceutical literature. The phrase "salicylic acid"
refers to salicylic acid or salicylate.
Concentrations of PG and other ingredients described in this application are all based on weight. The effective concentration of PG may range from about 5%
to about 100%, about 8% to about 100%, about 10% to about 100%, about 15% to about 100%, about 20% to about 100%, about 25% to about 100%, about 50% to about 100%, about 10% to about 90%, about 15% to about 90%, and about 20% to about 90%, or preferably from about 25% to about 85% or from about 50% to about 90%. Use of pure (100%) PG is expected to produce the most dramatic effect of killing P. acnes. However, it may cause some minor skin irritation to the lesion of acne or to sensitive skin. Inclusion of some glycerin such as 5% to 20%
soothes the skin and eliminates the itching and tingling caused by PG (Example 2).
The dosage form used may include a suitable amount of water, glycerin, other solvent(s), electrolyte(s), pH modifier(s), surfactant(s), absorption enhancer(s), emulsifier(s), thickener(s), fragrant(s), preservative(s), or a mixture thereof.
Although not required, the dosage form may also include one or more optional or additional anti-acne ingredients, including but not limited to salicylic acid, salicylate, benzoyl peroxide, metronidazole, erythromycin, tetracyclines and their derivatives, macrolides, clindamycin, minocycline, mecloycline, cloxycycline, azithromycin, clarithromycin, retinoids, azelaic acid, polyvalent metal compounds, picolinic acids, dapsone, anti-inflammatory compounds and astringents or a mixture thereof.
Salicylic acid is a Food-and-Drug-Administration-approved over-the-counter drug for treating acne because of its comedolytic property. This, and benzoyl peroxide, an anti-P. acnes drug, and many other ingredients (up to 30 or more) are often employed to form a 3- or 4- step treatment regime for acne. Skin dryness and irritation is a known problem associated with the above regime.
The novel combination of the PG and salicylic acid in a liquid solution in the present invention offers many unique and important advantages such as high efficacy for both infectious (pustular or papular) and non-infectious (whiteheads and blackheads in Example 6) components of acne, very low potential for allergic and adverse effects (both compounds being natural compounds), soothing, moisturizing, smoothing and firming effect on skin (Example 7), causing no pitting and scarring, a simple one-step method or a simple "all-in-one" method, great convenience for travelers (not carrying 3 or 4 bottles) and apparent economy. Furthermore, it can be used for rosacea treatment (Example 7). The present invention may also be useful to treat other bacterial skin infections. The concentration of salicylic acid or salicylate may range from about 0.05% to about 2% or from about 0.05% to about 3% or about 0.05% to about 6%. The dosage form may include glycerin ranging from about 5%
to about 20% for skin-soothing effect (Example 2).
For killing or inhibiting P. acnes or for treating acne or rosacea breakouts, dosage preparation can be applied as thin layers up to several times a day to the area of lesions or prophylactically to the area that may have new breakouts later.
Therefore, the present invention provides a novel method for treating acne and rosacea consisting essentially of, or comprising-topically applying a therapeutically effective amount of propylene glycol in the absence or presence of a therapeutically effective amount of salicylic acid or other anti-acne or anti-rosacea compounds in a pharmaceutically acceptable dosage form to the area of lesion of acne or rosacea.
The present invention is illustrated by the following non-limiting examples.
Examples Example 1 20% and 65% PG in Water for in vitro Time-Kill Studies An aqueous solution containing 20 or 65% PG was prepared by mixing PG
and water in a proper proportion for the standard time-kill study using Propionibacterium acnes ATCC #6919. For the 20% PG solution 47% and 98% of the bacteria were killed at one and five hours, respectively. For the 65% PG
solution 91 % and 99.6% of the bacteria were killed at one in and five hours, respectfully.
The initial bacteria count was 1.78 x 106 CFU/mL. Much higher PG solutions are expected to produce much higher killing rates.
Example 2 80% PG in Water for Acne Treatment: A Dramatic Effect The above aqueous PG solution was directly applied as thin layers to several infectious papular acnes in the forehead of an adult. The infection (inflammation) appeared to completely disappear in 8 hours indicating a virtual healing only after one application. On another day, a larger papular acne was also practically healed in about 8 hours after only one application without scarring and pitting. Mild itching and tingling lasting about three minutes occurred in both studies. These minor adverse effects were totally avoided when some glycerin (about 10%) was added to the mixture. No special cleansing of the lesion or skin is required for all the studies described here and below, hence it is a truly simple one-step method or "all-in-one"
method.
Example 3 20%, 40% and 60% PG in Water for Acne Treatment The above PG solutions were used to treat papular and pustuler acnes on the face on different occasions in a subject. Complete healing was achieved after several applications in 2 to 3 days without pitting and scarring. No itching or tingling occurred.
Example 4 75% or 80% PG Solution for Acne Treatment: A Dramatic Prophylactic Effect An aqueous solution containing 75% PG was employed to successfully treat various sizes of pastular and papular acnes in 4 adults. Daily applications were also performed in two adults for about one month without any side effects and with a clear sign of completely inhibiting new infectious acne formation indicating an excellent prophylactic effect. This was also the case with an 80% PG solution containing about 10% of glycerin.
Example 5 Daily application of 90% PG or 100% PG in Adults without Acne Pure (100%) PG or 90% PG in water was applied repeatedly to the normal skin of face and arm in 2 adults for several days. No adverse reactions were observed.
Example 6 75% PG - 0.5% Salicylic Solution for Treatment of Rosacea and Acne The above PG-salicylic acid solution was applied twice a day to the area of rosacea lesion in one subject and satisfactory results to quickly control breakouts and redness were obtained. The solution was also used to very successfully treat acne in two subjects without any adverse effects. Furthermore, the solution was highly effective against whiteheads and slower in response against blackheads;
a higher salicylic acid concentration should be more efficacious. The PG is an excellent solvent for salicylic acid in this preparation.
Example 4 75% or 80% PG Solution for Acne Treatment: A Dramatic Prophylactic Effect An aqueous solution containing 75% PG was employed to successfully treat various sizes of pastular and papular acnes in 4 adults. Daily applications were also performed in two adults for about one month without any side effects and with a clear sign of completely inhibiting new infectious acne formation indicating an excellent prophylactic effect. This was also the case with an 80% PG solution containing about 10% of glycerin.
Example 5 Daily application of 90% PG or 100% PG in Adults without Acne Pure (100%) PG or 90% PG in water was applied repeatedly to the normal skin of face and arm in 2 adults for several days. No adverse reactions were observed.
Example 6 75% PG - 0.5% Salicylic Solution for Treatment of Rosacea and Acne The above PG-salicylic acid solution was applied twice a day to the area of rosacea lesion in one subject and satisfactory results to quickly control breakouts and redness were obtained. The solution was also used to very successfully treat acne in two subjects without any adverse effects. Furthermore, the solution was highly effective against whiteheads and slower in response against blackheads;
a higher salicylic acid concentration should be more efficacious. The PG is an excellent solvent for salicylic acid in this preparation.
Example 7 Tissue-healing and Skin Firming Properties of PG
In all the studies conducted, PG solutions resulted in rapid healing of acne lesions without pitting and scarring. Furthermore, the applied areas of skin became smoother and firmer after about one month of daily use. These results indicate a tissue-healing and tissue-growth-promoting property of PG that is similar to the skin-firming phenomenon observed with a similar type of compound, glycerin (Chiou et al., US patent no. 6,616,923, B1; unpublished observations).
It is to be understood that the above descriptions are intended to be illustrative, and not restrictive. One skilled in the art will be able to ascertain, without any more routine experimentation, many reference to specific embodiments described herein. These equivalents are intended to be encompassed by the following claims.
In all the studies conducted, PG solutions resulted in rapid healing of acne lesions without pitting and scarring. Furthermore, the applied areas of skin became smoother and firmer after about one month of daily use. These results indicate a tissue-healing and tissue-growth-promoting property of PG that is similar to the skin-firming phenomenon observed with a similar type of compound, glycerin (Chiou et al., US patent no. 6,616,923, B1; unpublished observations).
It is to be understood that the above descriptions are intended to be illustrative, and not restrictive. One skilled in the art will be able to ascertain, without any more routine experimentation, many reference to specific embodiments described herein. These equivalents are intended to be encompassed by the following claims.
Claims (10)
1. A method for killing and/or inhibiting Propionibacterium acnes in a mammalian skin disorder comprising topically applying a therapeutically effective amount of propylene glycol alone or in combination with a therapeutically effective amount of salicylic acid in a pharmaceutically acceptable dosage form to the area of skin disorder.
2. The method of claim 1 wherein the skin disorder is acne and the concentrations of propylene glycol and salicylic acid range from about 5% to about 100% by weight and from about 0.05% to about 6% by weight, respectively.
3. A method of treating acne or rosacea comprising topically applying a composition comprising a therapeutically effective amount of propylene glycol in a pharmaceutically acceptable dosage form to the area of lesion of the acne or the area of lesion of the rosacea.
4. The method of claim 3, wherein the composition further comprises salicylic acid.
5. The method of claim 3, wherein the treating acne is to the area of lesion of the acne.
6. The method of claim 3, wherein the treating rosacea is to the area of lesion of the rosacea.
7. The method of claim 4 or claim 6, wherein the concentrations of propylene glycol and salicylic acid range from about 5% to about 100% by weight and from about 0.05% to about 6% by weight, respectively.
8. The method of any of claims 1 and 5-6, wherein the concentration of propylene glycol ranges from about 10% to about 100% by weight.
9. The method of any of claims 1 and 5-6, wherein the concentration of propylene glycol ranges from about 20% to about 100% by weight.
10. The method of any of claims 1 and 5-6, wherein the concentration of propylene glycol ranges from about 50% to about 100% by weight.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/244,924 | 2008-10-03 | ||
| US12/244,924 US8846646B2 (en) | 2008-10-03 | 2008-10-03 | Topical treatment of skin infection |
| PCT/US2009/058607 WO2010039654A2 (en) | 2008-10-03 | 2009-09-28 | Topical treatment of skin infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2742389A1 true CA2742389A1 (en) | 2010-04-08 |
Family
ID=42074140
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2742389A Abandoned CA2742389A1 (en) | 2008-10-03 | 2009-09-28 | Topical treatment of skin infection |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8846646B2 (en) |
| JP (1) | JP2012504624A (en) |
| KR (1) | KR20110074513A (en) |
| CN (1) | CN102159198A (en) |
| CA (1) | CA2742389A1 (en) |
| GB (1) | GB2476446A (en) |
| WO (1) | WO2010039654A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8846646B2 (en) | 2008-10-03 | 2014-09-30 | Winlind Skincare, Llc | Topical treatment of skin infection |
| US8513225B2 (en) * | 2008-10-03 | 2013-08-20 | Winlind Skincare, Llc | Composition and method for topical treatment of skin lesions |
| GB201112657D0 (en) * | 2011-07-22 | 2011-09-07 | Lowe Nicholas J | Compositions for treatment of skin disorders |
| CN103816165B (en) * | 2014-03-11 | 2019-03-01 | 北京德默高科医药技术有限公司 | A kind of composition for treating acne |
| BR112017004889A2 (en) | 2014-09-12 | 2017-12-05 | Antibiotx Aps | antibacterial use of halogenated salicylanilides |
| GB201509326D0 (en) | 2015-05-29 | 2015-07-15 | Antibio Tx Aps | Novel use |
| US10456366B2 (en) * | 2017-11-29 | 2019-10-29 | Chiou Consulting, Inc. | Composition and methods for tissue regeneration |
| US11419834B2 (en) | 2019-02-25 | 2022-08-23 | Rhode Island Hospital | Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide |
| CN112438899A (en) * | 2020-12-16 | 2021-03-05 | 广东丸美生物技术股份有限公司 | Skin care composition with acne conditioning effect and application thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2581542B1 (en) | 1985-05-07 | 1988-02-19 | Oreal | TOPICAL COMPOSITIONS FOR THE TREATMENT OF SKIN BASED ON SALICYLIC ACID DERIVATIVES |
| US5525635A (en) | 1986-02-04 | 1996-06-11 | Moberg; Sven | Pharmaceutical compositions containing propylene glycol and/or polyethylene glycol and urea as active main components and use thereof |
| US4883660A (en) * | 1988-10-17 | 1989-11-28 | Thames Pharmacal Co., Inc. | Gel bases for pharmaceutical compositions |
| US5549888A (en) | 1994-01-31 | 1996-08-27 | Procter & Gamble | Aqueous topical anti-acne compositions of low pH |
| US5569651A (en) * | 1995-03-03 | 1996-10-29 | Avon Products, Inc. | Gentle anti-acne composition |
| US5667790A (en) | 1995-08-14 | 1997-09-16 | Sellers, Jr.; Billy B. | Aluminum chlorhydrate as a treatment for acne and rosacea |
| US5753637A (en) * | 1996-10-09 | 1998-05-19 | Ideal Ideas, Inc. | Method of treating acne conditions |
| US6455065B1 (en) | 1999-05-18 | 2002-09-24 | Lectec Corporation | Therapeutic method for treating acne or isolated pimples and adhesive patch therefor |
| US6616923B1 (en) | 2002-07-26 | 2003-09-09 | Chiou Consulting, Inc. | Aqueous compositions for facial cosmetics |
| US7887842B2 (en) | 2003-02-07 | 2011-02-15 | Teikoku Pharma Usa, Inc. | Methods of administering a dermatological agent to a subject |
| US7258875B2 (en) | 2003-12-04 | 2007-08-21 | Chiou Consulting, Inc. | Compositions and methods for topical treatment of skin infection |
| US8846646B2 (en) | 2008-10-03 | 2014-09-30 | Winlind Skincare, Llc | Topical treatment of skin infection |
-
2008
- 2008-10-03 US US12/244,924 patent/US8846646B2/en active Active
-
2009
- 2009-09-28 WO PCT/US2009/058607 patent/WO2010039654A2/en active Application Filing
- 2009-09-28 CA CA2742389A patent/CA2742389A1/en not_active Abandoned
- 2009-09-28 KR KR1020117006688A patent/KR20110074513A/en not_active Application Discontinuation
- 2009-09-28 CN CN2009801367528A patent/CN102159198A/en active Pending
- 2009-09-28 JP JP2011530129A patent/JP2012504624A/en active Pending
- 2009-09-28 GB GB1107350A patent/GB2476446A/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US8846646B2 (en) | 2014-09-30 |
| GB2476446A (en) | 2011-06-22 |
| KR20110074513A (en) | 2011-06-30 |
| JP2012504624A (en) | 2012-02-23 |
| GB201107350D0 (en) | 2011-06-15 |
| US20100087403A1 (en) | 2010-04-08 |
| WO2010039654A3 (en) | 2010-07-01 |
| WO2010039654A2 (en) | 2010-04-08 |
| CN102159198A (en) | 2011-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8846646B2 (en) | Topical treatment of skin infection | |
| JP2668800B2 (en) | Topical treatment for skin diseases | |
| US8679552B2 (en) | Acne vulgaris treatment regimen | |
| US7258875B2 (en) | Compositions and methods for topical treatment of skin infection | |
| US6096326A (en) | Skin care compositions and use | |
| US20070003585A1 (en) | Topical skin treating compositions | |
| US20080038219A1 (en) | Novel Composition for a Topical Skin Treatment Base and Medicated Applications Thereof | |
| US20040171561A1 (en) | Topical formulations for treatment of rosacea | |
| WO2013014427A1 (en) | Compositions for treatment of skin disorders | |
| CA2769640A1 (en) | Combination of dapsone with adapalene | |
| US8513225B2 (en) | Composition and method for topical treatment of skin lesions | |
| US7655255B2 (en) | Topical composition for transdermal administration | |
| US20110117182A1 (en) | Combination of dapsone with other anti-acne agents | |
| JP2015530380A (en) | Composition for treating psoriasis | |
| US5667790A (en) | Aluminum chlorhydrate as a treatment for acne and rosacea | |
| US4034114A (en) | Treatment of skin keratoses with retinal | |
| AU2008203101A1 (en) | Topical compositions comprising telmesteine for treating dermatological disorders | |
| WO2014042604A1 (en) | Clindamycin phosphate, salicylic acid and tea tree oil combinations | |
| DK165938B (en) | TOPIC AGENT FOR TREATMENT OF NON-INFLAMMATORY ACNE | |
| EP2620146A1 (en) | Ibuprofen for treating actinic keratosis | |
| JPH0429934A (en) | Externally applicable composition containing extracted essence of ginkgo leaf | |
| JPS6054932B2 (en) | therapeutic composition | |
| WO1983000628A1 (en) | A method of treating acne vulgaris and composition containing carbamide peroxide | |
| US20080206363A1 (en) | Skin stabilizer preparation | |
| Garbe et al. | Topical therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20130930 |